Corline Biomedical: Our view on the phase I data

Research Note

2020-06-10

17:15

Redeye reiterate its positive stance towards Corline following the release of Phase I data with its lead candidate Renaparin. As stated in our initiation report, we saw good prospects of a positive outcome and assigned the trial a probability of success of 85%. With today’s encouraging safety data, we now consider the asset Phase II-ready and raise of our Base case to SEK 35 (30).

LS

Ludvig Svensson

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.